Epigenetic targets of arsenic: emphasis on epigenetic modifications during carcinogenesis.

Role of MCP-1 in alcohol-induced aggressiveness of colorectal cancer cells.

Arf6 controls platelet spreading and clot retraction via integrin αIIbβ3 trafficking.

Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity.

Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity.

[Anonymous].  2016.  Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity.. Oncotarget. 7(31):49699-49709.

TRAF3 negatively regulates platelet activation and thrombosis.

Human Cancer and Platelet Interaction, a Potential Therapeutic Target.

A New Mouse Model for Introduction of Aortic Aneurysm by Implantation of Deoxycorticosterone Acetate Pellets or Aldosterone Infusion in the Presence of High Salt.

A New Mouse Model for Introduction of Aortic Aneurysm by Implantation of Deoxycorticosterone Acetate Pellets or Aldosterone Infusion in the Presence of High Salt.

[Anonymous].  2017.  A New Mouse Model for Introduction of Aortic Aneurysm by Implantation of Deoxycorticosterone Acetate Pellets or Aldosterone Infusion in the Presence of High Salt.. Methods in molecular biology (Clifton, N.J.). 1614:155-163.

Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells.

Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells.

The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms.

The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms.

[Anonymous].  2011.  The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms.. Anticancer research. 31(3):813-23.